Main MOA brimonidine in glaucoma -
Brimonidine (0.2% : 2 times/day). It is a selective alpha-2-adrenergic agonist and lowers IOP by decreasing aqueous production. Because of increased allergic reactions and tachyphylaxis rates it is not considered the drug of first choice in POAG. It is used as second drug of choice and also for combination therapy with other drugs. Ref.AK Khurana 4th edition page no 223
Decreased aqueous secretion
Increased trabecular outflow
Increased uveoscleral outflow
Reduce vitreous volume
Glaucoma